AIMS: The TRPV1, transient receptor potential vanilloid type 1, agonist capsaicin is considered to be beneficial for cardiovascular health because it dilates coronary arteries through an endothelial-dependent mechanism and may slow atheroma progression. However, recent reports indicate that high doses of capsaicin may constrict coronary arterioles and even provoke myocardial infarction. Thus far, the mechanisms by which TRPV1 activation modulates coronary vascular tone remain poorly understood. This investigation examined whether there is a synergistic interplay between locally acting vasoconstrictive pro-inflammatory hormones (autacoids) and capsaicin effects in the coronary circulation. METHODS AND RESULTS: Experiments were performed in canine conduit coronary artery rings and isolated smooth muscle cells (CASMCs). Isometric tension measurements revealed that 1-10 μM capsaicin alone did not affect resting tension of coronary artery rings. In contrast, in endothelium-intact rings pre-contracted with a Gq/11-coupled FP/TP (prostaglandin F/thromboxane) receptor agonist, prostaglandin F2α (PGF2α; 10 μM), capsaicin first induced transient dilation that was followed by sustained contraction. In endothelium-denuded rings pre-contracted with PGF2α or thromboxane analogue U46619 (1 μM, a TP receptor agonist), capsaicin induced only sustained contraction. Blockers of the TP receptor or TRPV1 significantly inhibited capsaicin effects, but these were still observed in the presence of 50 μM nifedipine and 70 mM KCl. Capsaicin also potentiated 20 mM KCl-induced contractions. Fluorescence imaging experiments in CASMCs revealed that the Gq/11-phospholipase C (PLC)-protein kinase C (PKC) and Ca(2+)-PLC-PKC pathways are likely involved in sensitizing CASMC TRPV1 channels. CONCLUSION: Capsaicin alone does not cause contractions in conduit canine coronary artery; however, pre-treatment with pro-inflammatory prostaglandin-thromboxane agonists may unmask capsaicin's vasoconstrictive potential. Published on behalf of the European Society of Cardiology. All rights reserved.
AIMS: The TRPV1, transient receptor potential vanilloid type 1, agonist capsaicin is considered to be beneficial for cardiovascular health because it dilates coronary arteries through an endothelial-dependent mechanism and may slow atheroma progression. However, recent reports indicate that high doses of capsaicin may constrict coronary arterioles and even provoke myocardial infarction. Thus far, the mechanisms by which TRPV1 activation modulates coronary vascular tone remain poorly understood. This investigation examined whether there is a synergistic interplay between locally acting vasoconstrictive pro-inflammatory hormones (autacoids) and capsaicin effects in the coronary circulation. METHODS AND RESULTS: Experiments were performed in canine conduit coronary artery rings and isolated smooth muscle cells (CASMCs). Isometric tension measurements revealed that 1-10 μM capsaicin alone did not affect resting tension of coronary artery rings. In contrast, in endothelium-intact rings pre-contracted with a Gq/11-coupled FP/TP (prostaglandin F/thromboxane) receptor agonist, prostaglandin F2α (PGF2α; 10 μM), capsaicin first induced transient dilation that was followed by sustained contraction. In endothelium-denuded rings pre-contracted with PGF2α or thromboxane analogue U46619 (1 μM, a TP receptor agonist), capsaicin induced only sustained contraction. Blockers of the TP receptor or TRPV1 significantly inhibited capsaicin effects, but these were still observed in the presence of 50 μM nifedipine and 70 mM KCl. Capsaicin also potentiated 20 mM KCl-induced contractions. Fluorescence imaging experiments in CASMCs revealed that the Gq/11-phospholipase C (PLC)-protein kinase C (PKC) and Ca(2+)-PLC-PKC pathways are likely involved in sensitizing CASMC TRPV1 channels. CONCLUSION:Capsaicin alone does not cause contractions in conduit canine coronary artery; however, pre-treatment with pro-inflammatory prostaglandin-thromboxane agonists may unmask capsaicin's vasoconstrictive potential. Published on behalf of the European Society of Cardiology. All rights reserved.
Authors: Á Czikora; E Lizanecz; P Bakó; I Rutkai; F Ruzsnavszky; J Magyar; R Pórszász; T Kark; A Facskó; Z Papp; I Édes; A Tóth Journal: Br J Pharmacol Date: 2012-03 Impact factor: 8.739
Authors: Xingjuan Chen; Weiyang Sun; Nicholas G Gianaris; Ashley M Riley; Theodore R Cummins; Jill C Fehrenbacher; Alexander G Obukhov Journal: J Biol Chem Date: 2014-02-25 Impact factor: 5.157
Authors: Daniel J Cavanaugh; Alexander T Chesler; Alexander C Jackson; Yaron M Sigal; Hiroki Yamanaka; Rebecca Grant; Dajan O'Donnell; Roger A Nicoll; Nirao M Shah; David Julius; Allan I Basbaum Journal: J Neurosci Date: 2011-03-30 Impact factor: 6.167
Authors: Daniel J DelloStritto; Patrick J Connell; Gregory M Dick; Ibra S Fancher; Brittany Klarich; Joseph N Fahmy; Patrick T Kang; Yeong-Renn Chen; Derek S Damron; Charles K Thodeti; Ian N Bratz Journal: Basic Res Cardiol Date: 2016-02-24 Impact factor: 17.165
Authors: Aleksandar Kibel; Kristina Selthofer-Relatic; Ines Drenjancevic; Tatjana Bacun; Ivica Bosnjak; Dijana Kibel; Mario Gros Journal: J Int Med Res Date: 2017-01-12 Impact factor: 1.671
Authors: Ankush M Korishettar; Yoshinori Nishijima; Zhihao Wang; Yangjing Xie; Juan Fang; David A Wilcox; David X Zhang Journal: Br J Pharmacol Date: 2020-12-27 Impact factor: 9.473
Authors: Wennan Li; Xingjuan Chen; Ashley M Riley; S Christopher Hiett; Constance J Temm; Eleni Beli; Xin Long; Saikat Chakraborty; Mouhamad Alloosh; Fletcher A White; Maria B Grant; Michael Sturek; Alexander G Obukhov Journal: Basic Res Cardiol Date: 2017-07-29 Impact factor: 17.165
Authors: Pritam Sinharoy; Ian N Bratz; Sayantani Sinha; Loral E Showalter; Spencer R Andrei; Derek S Damron Journal: PLoS One Date: 2017-06-23 Impact factor: 3.240
Authors: Xingjuan Chen; Natalie N Taylor-Nguyen; Ashley M Riley; B Paul Herring; Fletcher A White; Alexander G Obukhov Journal: J Neuroinflammation Date: 2019-01-31 Impact factor: 8.322